INNATE PHARMA (EPA:IPH) Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) today updates on it next meetings with analysts and investors

Transparency directive : regulatory news

07/04/2010 19:13

PRESS RELEASE

     INNATE PHARMA UPDATES ON ITS NEXT MEETINGS WITH ANALYSTS AND INVESTORS

Marseilles, France, April 7, 2010

Innate Pharma (the "Company" - Euronext Paris: FR0010331421 - IPH) today
announces its participation to the following analyst and investor conferences
in the coming weeks:

* CF&B Smallcap Event, April 12-13, 2010, in Paris, France: Innate Pharma will
  meet with French investors specialized in small and midcap companies;

* BioEquity Europe, May 19-20, 2010, in Zurich, Switzerland: Hervé Brailly, CEO
  of Innate Pharma, will present the Company to European investors specialized
  in the biotech and healthcare sectors.

Innate Pharma is committed to meet on a regular basis with the financial
community. Investors can also find updated information on the company's website
(www.innatepharma.com) and contact the investor relations team by writing to
investors@innatepharma.com.

About Innate Pharma:

Innate Pharma S.A. is a clinical-stage biopharmaceutical company developing
first-in-class immunotherapy drugs for cancer and other severe diseases. The
Company was incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006.
The Company has two drug candidates currently in Phase II clinical trials. Two
of its preclinical programs are out-licensed to Novo Nordisk A/S.

Innate Pharma is based in Marseilles, France, and had 80 employees as at
December 31, 2009.

Learn more about Innate-Pharma at www.innate-pharma.com

Practical Information about Innate Pharma shares:

ISIN code      FR0010331421
Ticker code    IPH

Disclaimer:

This press release contains information on the markets on which the Company
operates and forward-looking statements. Although the Company believes this
information and these expectations are based on reasonable assumptions, this
information and these forward-looking statements are subject to numerous risks
and uncertainties, which could cause actual results to differ materially from
those anticipated. For a discussion of risks and uncertainties which could
cause the Company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking statements,
please refer to the Risk Factors ("Facteurs de Risque") section of the Document
de Reference prospectus filed with the AMF, which is available on the AMF
website (www.amf-france.org) or on Innate Pharma's website
(www.innatepharma.com).

For additional information, please contact:

Innate Pharma                     Alize Public Relations
Laure-Hélène Mercier,             Caroline Carmagnol
Director, Investor Relations      Phone: +33 (0)1 42 68 86 40
Phone: +33 (0)4 30 30 30 87       Mobile: +33 (0)6 64 18 99 59
investors@innate-pharma.fr        caroline@alizerp.com

100407 IPH Next events

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) today updates on it next meetings with analysts and investors

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories